PCOS Renamed Polyendocrine Metabolic Ovarian Syndrome

A major endocrine condition affecting hundreds of millions of women globally has a new name. According to a review published in the journal Fertility and Sterility, polycystic ovary syndrome (PCOS) is now formally known as polyendocrine metabolic ovarian syndrome (PMOS).

A systematic historical review led by Professor Helena J. Teede of Monash University traces a 30-year case for change. The research, which screened literature from 1995 to 2026, found the old name was repeatedly challenged on scientific and systemic grounds. The review is authored by an international team including Helena J. Teede, Saeede Saadati, Rachel Morman, Mahnaz Bahri Khomami, Melanie G. Cree, Robert J. Norman, and Terhi Piltonen. The authors are affiliated with institutions in Australia, the United States, Finland, and the United Kingdom, including Monash University, the University of Colorado, the University of Adelaide, the University of Oulu, and the UK charity Verity.

Why The Old Name Was Problematic

Experts argued the term 'polycystic ovary syndrome' was inaccurate. The name incorrectly suggested a primary issue of increased ovarian cysts. In reality, the condition involves a much broader set of endocrine and metabolic dysfunctions. This misnomer contributed to widespread problems.

The inaccuracy led to limited research focus, poor data capture, and inadequate education for healthcare providers. It also caused significant diagnostic delays and widespread patient dissatisfaction with care. The name's narrow focus on ovaries neglected the disorder's full impact on women's health.

The Path To A Global Consensus

For years, isolated expert opinions calling for a rename failed to gain traction. The turning point came with a patient-co-led, multistep global process in 2026. This effort involved 56 organizations and gathered survey responses from more than 22,000 people.

The process generated a clear mandate for change. It explored potential risks and set implementation priorities. The outcome was a 97% consensus among stakeholders to adopt the new name: polyendocrine metabolic ovarian syndrome.

Professor Teede and her international co-authors detail this journey in their paper. The correspondence author is Professor Helena J. Teede AM of the Monash Centre for Health Research and Implementation. The paper was received on August 10, 2026, revised on August 24, 2026, accepted on August 24, 2026, and published online on September 1, 2026.

Implementing The New Name

Implementation of the PMOS name now spans multiple critical areas. Work is underway to update international coding and disease classification systems. Research protocols, clinical guidelines, and medical education materials are being revised.

Early reception to the change has been predominantly positive. The authors report early adoption and positive feedback across media, social media, and in academic literature. Professional societies are beginning to incorporate the new terminology.

The review concludes that this evidence-based renaming aims to better reflect the condition's nature. It seeks to improve research, diagnosis, and care for the hundreds of millions of women affected worldwide. The authors note that no funding was received to complete this work. Disclosures include that Professor Teede is supported by an Australian NHMRC fellowship and holds a voluntary role as President of the International Society of Endocrinology. Co-author Rachel Morman is Chair of Trustees of Verity, a PMOS charity in the UK, and received a travel grant for the 2026 European Society of Endocrinology conference. Co-author Melanie G. Cree reported support from the NIH and received consulting fees from several pharmaceutical companies.